Article ; Online: Degenerative Aortic Stenosis, Dyslipidemia and Possibilities of Medical Treatment.
2018 Volume 54, Issue 2
Abstract: Degenerative aortic stenosis (DAS) is the most frequently diagnosed heart valve disease in Europe and North America. DAS is a chronic progressive disease which resembles development of atherosclerosis. Endothelial dysfunction, lipid infiltration, ... ...
| Abstract | Degenerative aortic stenosis (DAS) is the most frequently diagnosed heart valve disease in Europe and North America. DAS is a chronic progressive disease which resembles development of atherosclerosis. Endothelial dysfunction, lipid infiltration, calcification and ossification are evidenced in both diseases. The same risk factors such as older age, male sex, smoking, and elevated levels of lipids are identified. The effect of smoking, visceral obesity, metabolic syndrome, hypercholesterolemia, low-density lipoprotein, high-density lipoprotein, lipoprotein(a), adiponectin and apolipoprotein(a) on development of DAS are being studied. The search for genetic ties between disorders of lipid metabolism and DAS has been started. DAS is characterized by a long symptom-free period which can last for several decades. Aortic valve replacement surgery is necessary when the symptoms occur. The lipid-lowering therapy effect on stopping or at least slowing down the progression of DAS was studied. However, the results of the conducted clinical trials are controversial. In addition, calcium homeostasis, bone metabolism and calcinosis-reducing medication are being studied. Although prospective randomized clinical trials have not demonstrated any positive effect of statins used for slowing progression of the disease, statins are still recommended for patients with dyslipidemia. Recent study has suggested that a specific modification of treatment, based on severity of disease, may have a beneficial effect in patients with aortic sclerosis and mild DAS. New clinical studies analyzing new treatment possibilities which could correct the natural course of the disease and reduce the need for aortic valve replacement by surgery or transcatheter treatment interventions are needed. |
|---|---|
| MeSH term(s) | Animals ; Aortic Valve/pathology ; Aortic Valve Stenosis/etiology ; Aortic Valve Stenosis/therapy ; Asymptomatic Diseases/therapy ; Calcinosis/etiology ; Calcinosis/therapy ; Chronic Disease ; Disease Progression ; Dyslipidemias/complications ; Dyslipidemias/therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/complications ; Hypercholesterolemia/drug therapy ; Mice ; Risk Factors |
| Chemical Substances | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| Language | English |
| Publishing date | 2018-04-25 |
| Publishing country | Switzerland |
| Document type | Journal Article ; Review |
| ZDB-ID | 2188113-3 |
| ISSN | 1648-9144 ; 1010-660X |
| ISSN (online) | 1648-9144 |
| ISSN | 1010-660X |
| DOI | 10.3390/medicina54020024 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6270: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.